Sorrento Therapeutics skyrockets 244% after claiming a breakthrough on COVID-19 drug
May 17, 2020, 18:47 IST
- Shares of Sorrento Therapeutics spiked as much as 244% on Friday after the company claimed an antibody it's developing showed 100% inhibition of the COVID-19 virus in preclinical studies.
- The small biotechnology company said it aims to create an antibody cocktail that would act as a "protective shield" against coronavirus.
- Sorrento said full results of its antibody candidate will be submitted to a peer-reviewed publication shortly.
- Visit Business Insider's homepage for more stories.
Advertisement
Sorrento Therapeutics skyrocketed as much as 244% on Friday after the company claimed an antibody it's developing showed 100% inhibition of the COVID-19 virus in preclinical studies.The small biotechnology company plans to "generate an antibody cocktail product that would act as a 'protective shield' against SARS-CoV-2 coronavirus."
Sorrento said it will ask regulators for priority evaluation and an accelerated review of its drug candidate.
The company hopes to receive government support and partner with a pharmaceutical company to scale up manufacturing of its coronavirus candidate, if proven successful.
Read more: Buy these 13 tech stocks that are abnormally disconnected from Wall Street's expectations for profit growth and poised to rocket higher, Credit Suisse says
Advertisement
Sorrento's market value surged from $549 million at yesterday's close to roughly $1.9 billion at Friday's intraday highs.